Home > News > Scanning Laser Ophthalmoscope in the Management of Age-related Macular Degeneration
Imaging, Macular Degeneration, Retina/Vitreous
Read Time: 2 mins

Scanning Laser Ophthalmoscope in the Management of Age-related Macular Degeneration

Published Online: August 5th 2012 European Ophthalmic Review, 2012;6(4):242-9 DOI: http://doi.org/10.17925/EOR.2012.06.04.242
Authors: Nicole K Scripsema, Richard B Rosen
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Recent advances in retinal imaging have improved the evaluation and prognostication of age-related macular degeneration. The development and modification of the scanning laser ophthalmoscope (SLO) has played a pivotal role in our understanding of the disease. SLO has led to improved methods of visualising characteristics of the disease, such as drusen and alterations in autofluorescence, and also provided a platform for the quantification of structural and functional changes occurring as a result of the disease process. This article provides a review of the current literature on the impact and clinical utility of SLO devices for infrared viewing, fundus autofluorescence, microperimetry, and as integraded multimodal imaging systems such as optical coherence tomography and SLO.

Keywords

Age-related macular degeneration, scanning laser ophthalmoscope, autofluorescence, spectral-domain optical coherence tomography, microperimetry

Article:

Age-related macular degeneration (AMD) is the most common cause of irreversible central vision loss and legal blindness in developed countries.1–3 AMD represents a chronic disease with various phenotypic manifestations, disease stages and rates of progression over time. Severe vision loss results from choroidal neovascularisation (CNV), pigment epithelial detachment, or geographic atrophy (GA) of the retinal pigment epithelium (RPE).4 While CNV is the most common cause of vision loss, GA is responsible for approximately 20 % of severe visual impairment in AMD.5–8 The chronic nature of the disease, limited treatment options, and the ageing population are all factors suggesting that the prevalence of AMD will increase with time unless effective interventions are developed.

Retinal imaging plays a critical role in the detection and management of disease because it can reveal lesions difficult to visualise by funduscopic examination. Colour fundus photography is the standard imaging modality used for assessment and documentation of AMD. Fluorescein angiography provides additional functional information on vascular involvement, which is important in the detection of CNV and other complications of advanced disease that involve disturbance of the blood–retinal barrier. The scanning laser ophthalmoscope (SLO) adds the ability to test and image the retina in a point-by-point fashion, which enhances the evaluation of structural and functional changes in the disease process of exudative and non-exudative AMD.

The SLO was originally developed by Pomeranzeff and Webb to provide high-contrast images of the retina at illumination levels 1/1,000 of those required for indirect ophthalmoscopy.9 The SLO scans a low energy laser beam (or other coherent illumination source such as the superluminescent diode) across the fundus and reconstructs images from reflected light, creating images with a higher level of contrast compared with fundus photography.10,11 The technology of the sweeping illumination source provides a platform from which additional testing such as fluorescein angiography, manual and automated perimetry, and reflectometry of cone pigment densities can be accomplished.10,12–15 Additional modifications of the device lead to the confocal SLO (cSLO), which uses light from a single plane for image reconstruction. By rejecting the returning scattered light, the cSLO provides improved contrast and complete retinal images (40°) without dilation of the pupil.11,16 Pupil dilation is not necessary but it is often done in practice to obtain higher quality images. Currently there are three modalities that use the cSLO technology in the detection and management of AMD: fundus autofluorescence (FAF), optical coherence tomography (OCT)/SLO, and microperimetry (MP). Modification of the aperture and light source has also generated the indirect, infrared (IR) and retro-mode SLO devices that provide additional methods for the assessment ofsubretinal disease. The aim of this article is to review recent findings in AMD research that relate to the application of these devices for earlydetection and monitoring of progression of disease, or response to therapeutic interventions.

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:
Disclosure

Nicole K Scripsema has no conflicts of interest to declare. Richard B Rosen is a member of the Scientific Advisory Board of OPKO/OTI (Miami, Florida). Support was received from the Bendheim-Lowenstein Retinal Fund.

Correspondence

Richard B Rosen, The Retina Center, Department of Ophthalmology, New York Eye and Ear Infirmary, 310 East 14th St, New York, NY 10003, US. E: rrosen@nyee.edu

Received

2011-09-05T00:00:00

References

  1. Attebo K, Mitchell P, Smith W, Visual acuity and the causes of visual loss in Australia, Ophthalmology, 1996;104:357–64.
  2. Klein R, Wang Q, Klein BEK, et al., The relationship of age-related maculopathy, cataract and glaucoma to visual acuity, Invest Ophthalmol Vis Sci, 1995;36:182–91.
  3. Leibowitz H, Kruger DE, Maunder LR, et al., The Framingham Eye Study Monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1977, Surv Ophthalmol, 1980;24:335–610.
  4. Klein R, Klein BE, Jensen SC, Meuer SM, The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study, Ophthalmology, 1997;104:7–21.
  5. Ferris FL III, Fine SL, Hyman L, Age-related macular degeneration and blindness due to neovascular maculopathy, Arch Ophthalmol, 1984;102:1640–2.
  6. Hyman LG, Lilienfeld AM, Ferris FL III, Fine SL, Senile macular degeneration: a case-control study, Am J Epidemiol, 1983;118:213–27.
  7. Klein R, Klein BE, Lee KE, et al., Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study, Am J Ophthalmol, 2006;142:539–49.
  8. Klein R, Klein BE, Knudtson MD, et al., Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study, Ophthalmology, 2007;114:253–62.
  9. Webb RH, Hughes GW, Pomerantzeff O, Flying spot TV ophthalmoscope, Appl Opt, 1980;19:2991–7.
  10. Mainster MA, Timberlake GT, Webb RH, Huges GW, Scanning laser ophthalmoscopy. Clinical applications, Ophthalmology 1982;89:852–7.
  11. Woon WH, Fitzke FW, Bird AC, Marshall J, Confocal imaging of the fundus using a scanning laser ophthalmoscope, Br J Ophthalmol, 1992;76:470–4.
  12. Elsner AE, Burns SA, Hughes GW, Webb RH, Reflectometry with a scanning laser ophthalmoscope, Appl Opt, 1992;31:3697–710.
  13. Elsner AE, Burns SA, Webb RH, Mapping cone photopigment optical density, J Opt Soc Am A, 1993;10:52–8.
  14. Johnson PT, Lewis GP, Talaga KC, et al. Drusen-associated degeneration in the retina, Invest Ophthalmol Vis Sci, 2003;44:4481–8.
  15. Marré M, Marré E, Erworbene Storungen des Farbensehens: Diagnostik, Stuttgart: Gustav Fischer Verlag, 1986.
  16. Webb RH, Hughes GW, Delori FC, Confocal scanning laser ophthalmoscope, Appl Opt, 1987;26:1492–9.
  17. Bird A, Age-related macular disease, Br J Ophthalmol, 1996;80:2–3.
  18. Holz FG, Bindewald-Wittich A, Fleckenstein M, et al., Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration, Am J Ophthalmol, 2007;143:463–72.
  19. Bonnin P, Launay F, Fauconnier T, [Our experience with clinical study of the eye in the near infrared region], Ophtalmologie, 1990;4:33–9.
  20. Elsner AE, Burns SA, Weiter JJ, Delori FC, Infrared imaging of sub-retinal structures in the human ocular fundus, Vision Res, 1996;36:191–205.
  21. Webb RH, Delori FC, How we see the retina. In: Marshall J (ed.) Laser technology in ophthalmology, Amsterdam: Kugler & Ghedini, 1988;3–14.
  22. Hartnett ME, Elsner AE, Characteristics of exudative age-related macular degeneration determined in vivo with confocal and indirect infrared imaging, Ophthalmology 1996;103:58–71.
  23. Wormington, C, Ophthalmic lasers, Philadelphia, PA: Butterworth-Heinemann, 2003.
  24. Acton JH, Cubbidge RP, King H, et al., Drusen detection in retro-mode imaging by a scanning laser ophthalmoscope, Acta Ophthalmol, 2011;89:e404–11.
  25. Bellmann C, Holz FG, Schapp O, et al., Topographie der Fundusautofluoreszenz mit einem neuen konfokalen Scanning-Laser- Ophthalmoskop, Der Ophthalmologe, 1997;94:385–91.
  26. Bindewald A, Jorzik JJ, Loesch A, et al., Visualisation of retinal pigment epithelial (RPE) cells in vivo using digital high resolution confocal scanning laser ophthalmoscopy, Am J Ophthalmol, 2004;137:556–8.
  27. Delori FC, Spectrophotometer for non-invasive measurement of intrinsic fluorescence and reflectance of the ocular fundus, Appl Optics, 1994;33:7429–52
  28. Holz FG, Bellmann C, Margaritidis M, et al., Patterns of increased in vivo fundus autofluorescence in the junctional zone of geographic atrophy of the retinal pigment epithelium associated with age-related macular degeneration, Graefes Arch Clin Exp Ophthalmol, 1999;237:145–52.
  29. von Rückmann A, Fitzke FW, Bird AC, Distribution of fundus autofluorescence with a scanning laser ophthalmoscope, Br J Ophthalmol, 1995;79:407–12.
  30. Delori FC, Fleckner MR, Goger DG, et al., Autofluorescence distribution associated with drusen in age-related macular degeneration, Invest Ophthalmol Vis Sci, 2000;41:496–504.
  31. Delori FC, Goger DG, Dorey CK, Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects, Invest Ophthalmol Vis Sci, 2001;42:1855–66.
  32. Dorey CK, Wu G, Ebenstein D, et al., Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration, Invest Ophthalmol Vis Sci, 1989;30:1691–9.

Further Resources

Share this Article
Related Content In Retina/Vitreous
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72